April 28, 2020
LEUVEN, BELGIUM - April 28, 2020 - Terumo Europe N.V. today announced that BioPearl™ Microspheres received CE Mark, making it an innovative new option for patients eligible for loco-regional embolization of target artery blood supply to liver cancer. BioPearl™ Microspheres, the next generation of drug eluting microspheres, are designed to preserve post-TACE target artery access, opening up the potential for cyclic treatment1,2.
"The availability of BioPearl™ Microspheres is an important milestone in Interventional Oncology as it is the first biodegradable drug-eluting microsphere loadable with 3 chemotherapeutic drugs (doxorubicin, idarubicin and epirubicin). BioPearl™ may further improve patient outcomes by enabling retreatment of the same target artery." said Peter Coenen, President of Interventional Systems Terumo EMEA. "BioPearl™ Microspheres are leading the way to new opportunities with a biodegradable (TACE) by allowing future treatment options to be kept open. BioPearl™ Microspheres represent Terumo's latest innovation complementing our loco-regional treatment portfolio."
Currently, Drug-Eluting Microsphere TACE (DEM-TACE) and conventional-TACE are both used worldwide. BioPearl™ Microspheres have been designed based upon clinicians' desire to have controlled drug elution while keeping future treatment options open. BioPearl™ Microspheres could change treatment algorithms and may offer more choices for patients.
"Interventional Oncology is not a stand-alone speciality and by working with medical oncologists, we will be able to optimize current and future treatments, namely by delivering drugs directly into the tumour. Through such collaboration, we may be able to reduce the dosage and improve the toxicity profile of anticancer drugs and ultimately improve the field." said Pr. Thierry De Baere from Institute Gustave Roussy in Villejuif - France. "BioPearl™ drug eluting Microspheres and its degradation profile is a significant next step toward enhancing localized drug delivery and hopefully improving patient outcomes."
1 Data on file - TR18-174B. BioPearl™ liver studies
2 Data on file -TR18 - 174C. BioPearl™ liver studies
Terumo Europe is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets and sells a vast range of medical devices in five main business units: Interventional Systems, Pharmaceutical Solutions, Medical Products, Cardiovascular Products and Diabetes Management. Terumo Europe EMEA headquarters and production facilities are located in Leuven (Belgium), production facility in Knowsley (UK), European Distribution Center in Genk (Belgium) and sales offices across EMEA. www.terumo-europe.com
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.
Corporate Communication Dept., Terumo Corporation
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.